Logo image
A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma
Journal article   Open access   Peer reviewed

A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma

Raju Kandimalla, Hideo Tomihara, Jasjit K. Banwait, Kensuke Yamamura, Gagandeep Singh, Hideo Baba and Ajay Goel
Clinical Cancer Research, Vol.26(14)
2020

Abstract

Aged Biomarkers, Tumor Carcinoma, Pancreatic Ductal Computational Biology Female Follow-Up Studies Gene Expression Profiling Gene Expression Regulation, Neoplastic Humans Male Middle Aged Models, Genetic Nomograms Pancreatic Neoplasms Risk Assessment Transcriptome Tumor Microenvironment CA 19-9 antigen formaldehyde transcriptome tumor marker 15 gene immune stromal and proliferation gene signature adult aged AHR gene Article cancer patient cancer prognosis cancer staging cancer survival CD160 gene CDC20 gene cell proliferation cohort analysis confidence interval controlled study female FOXP3 gene gene expression gene identification genetic database hazard ratio high risk patient human IFIT3 gene IL32 gene IL4 gene immune stromal and proliferation gene signature immunocompetent cell INHBA gene KDM6B gene low risk patient major clinical study male nomogram oncogene overall survival pancreas adenocarcinoma paraffin embedding patient identification PLD4 gene prediction proportional hazards model PVRL3 gene real time reverse transcription polymerase chain reaction RFC4 gene risk assessment RNA sequencing stroma cell TNFRSF4 gene TNFSF10 gene TNFSF18 gene tumor microenvironment validation study biological model biology follow up gene expression profiling gene expression regulation genetics immunology middle aged mortality nomogram pancreas carcinoma pancreas tumor procedures
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with dismal survival rates. Tumor microenvironment (TME), comprising of immune cells and cancer-associated fibroblasts, plays a key role in driving poor prognosis and resistance to chemotherapy. Herein, we aimed to identify a TME-associated, risk-stratification gene biomarker signature in PDAC. Experimental Design: The initial biomarker discovery was performed in The Cancer Genome Atlas (TCGA, n ¼ 163) transcriptomic data. This was followed by independent validation of the gene signature in the International Cancer Genome Consortium (ICGC, n ¼ 95), E-MTAB-6134 (n ¼ 288), and GSE71729 (n ¼ 123) datasets for predicting overall survival (OS), and for its ability to detect poor molecular subtypes. Clinical validation and nomogram establishment was undertaken by performing multivariate Cox regression analysis. Results: Our biomarker discovery effort identified a 15-gene immune, stromal, and proliferation (ISP) gene signature that significantly associated with poor OS [HR, 3.90; 95% confidence interval (CI), 2.36–6.41; P < 0.0001]. This signature also robustly predicted survival in three independent validation cohorts ICGC [HR, 2.63 (1.56–4.41); P < 0.0001], E-MTAB-6134 [HR, 1.53 (1.14–2.04); P ¼ 0.004], and GSE71729 [HR, 2.33 (1.49–3.63); P < 0.0001]. Interestingly, the ISP signature also permitted identification of poor molecular PDAC subtypes with excellent accuracy in all four cohorts; TCGA (AUC ¼ 0.94), ICGC (AUC ¼ 0.91), E-MTAB-6134 (AUC ¼ 0.80), and GSE71729 (AUC ¼ 0.83). The ISP-derived high-risk patients exhibited significantly poor OS in a clinical validation cohort [n ¼ 119; HR, 2.62 (1.50–4.56); P ¼ 0.0004]. A nomogram was established which included the ISP, CA19-9, and T- and N-stage for eventual clinical translation. Conclusions: We report a novel gene signature for risk-stratification and robust identification of patients with PDAC with poor molecular subtypes. ©2020 American Association for Cancer Research.
url
https://doi.org/10.1158/1078-0432.CCR-19-4044View
Published (Version of record) Open

Metrics

9 Record Views

Details

Logo image